AbbVie
Biopharmaceutical company developing and commercialising prescription medicines.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- AbbVie Inc.
- Entity type
- COMPANY
- Founded
- 2012
- Headquarters
- 1 North Waukegan Road, North Chicago, Illinois 60064
- Company size
- >5,000
- Market role
- Advertiser / Brand
- Ticker
- ABBV
- Official website
- news.abbvie.com
What AbbVie does
AbbVie creates value by researching, developing, manufacturing and commercialising prescription medicines protected by regulatory approvals, intellectual property and brand equity. Revenue is generated primarily through selling approved therapies into healthcare distribution and provider channels, supported by large-scale commercial, medical and regulatory operations.
Category differentiation
AbbVie is a pharmaceutical manufacturer, not an adtech, martech or media platform. It should not be confused with healthcare software vendors or advertising businesses serving pharma brands.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
AbbVie is a large US-headquartered biopharmaceutical company founded in 2012 and operating as a public company. It develops, manufactures and commercialises prescription medicines, generating revenue from the sale of branded therapies through healthcare channels. Its direct commercial customers are typically healthcare systems, hospitals, clinics, pharmacies, distributors and other institutional healthcare buyers rather than end consumers. Based on the information provided, AbbVie should be understood as a healthcare manufacturer and commercial pharmaceutical business, not as a media, software or advertising company.
Company news briefing
Briefing updated:
Building upon its acquisition of Apogee Therapeutics, AbbVie has further advanced its clinical and regulatory pipeline. Recent developments include FDA approval for JUVMO in Parkinson's disease, positive Phase 3 results for etentamig in multiple myeloma and atogepant in menstrual migraine, alongside real-world effectiveness data for VRAYLAR. Furthermore, AbbVie joined the Antibody Developability Consortium to leverage federated AI for drug discovery, submitted an EMA application for subcutaneous SKYRIZI in Crohn's disease, and showcased new lung cancer pipeline data.
Business model & monetisation
AbbVie’s monetisation model is primarily product sales of prescription medicines, with revenue realised through healthcare distribution, provider and pharmacy channels. The supplied data does not specify pricing mechanics, therapeutic areas, licensing income or service-based revenue, so the observable model is best described as commercial pharmaceutical sales.
Products & capabilities
No products with linked sources are available in this view.
Subsidiaries & acquisitions
- Washington Commanders
NFL franchise monetising fan attention through games, media, tickets and merchandise.
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
Recorded impact score: 5/5
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...
REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy
Health care / Biotech · Recorded impact score: 1/5
REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.
- 60% of Dose Level 3 participants (n=6/10) achieved >2-step DRSS improvement at 3 years post-treatment.
- No vision-threatening events or additional treatment for diabetic retinopathy observed in these participants.
AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued
Recorded impact score: 2/5
On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
Recorded impact score: 4/5
AbbVie announced positive Phase 3 results for atogepant in menstrual migraine, extending its leadership in migraine treatment. The company also declared a quarterly dividend of $1.73 per share and reported positive topline results from the Phase 3 CERVINO trial for etentamig in multiple myeloma.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Recorded impact score: 4.5/5
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...
Explore company relationships
Questions about AbbVie
What is AbbVie?
AbbVie is a US-based public biopharmaceutical company that develops, manufactures and commercialises prescription medicines.
Who uses AbbVie?
Its products are used within the healthcare ecosystem, with commercial relationships typically involving hospitals, clinics, pharmacies, distributors and other institutional healthcare buyers.
How does AbbVie make money?
AbbVie primarily makes money by selling branded prescription medicines through healthcare and pharmaceutical distribution channels.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
7 publicly documented primary sources and citations linked across the market graph.
Continue your research on AbbVie
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.